1 / 7

NAPHTHALENE - an update -

NAPHTHALENE - an update -. JOHN P. HINZ Health Risk Assessment Branch Air Force Institute for Operational Health Brooks City-Base, TX. JPH: TSERAWG (20Sep06). OUTLINE. Naphthalene “State of the Science Symposium” Mitretek Paper Outline of Industry’s Approach AFIOH’s Tox & Epi Workshop.

stormy
Download Presentation

NAPHTHALENE - an update -

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. NAPHTHALENE- an update - JOHN P. HINZ Health Risk Assessment Branch Air Force Institute for Operational Health Brooks City-Base, TX JPH: TSERAWG (20Sep06)

  2. OUTLINE • Naphthalene “State of the Science Symposium” • Mitretek Paper • Outline of Industry’s Approach • AFIOH’s Tox & Epi Workshop

  3. NAPHTHALENE “State of the Science Symposium” • Scheduled for 9-12Oct06, Monterey, CA • Recruited distinguished roster of independent researchers & naphthalene experts for a circumspect accounting of what is known/unknown • Focused around 4 basic issues/themes • Animal data • Human data • Anatomy, physiology, metabolic activation/deactivation • Mechanisms of carcinogenesis • Uncertainty analysis • Guidance on best directions for research

  4. MITRETEK PAPERCarcinogenicity of Naphthalene – Commentary & Suggestions • OSD tasker to clarify/highlight issues, data gaps, possible studies to address areas of uncertainty • Intended for submission to NS3 & EPA • Issues, data gaps & uncertainties • Are the NTP studies unconfounded? • Is the rodent model pertinent & predictive of human risk? • Is the LMS model the appropriate tool, or is N a threshold carcinogen? Or both…? • What does epidemiology, and our experience, tell us? • Suggestions for research/studies to clarify areas of uncertainty • Finalize & clear with OSD & legal, etc.; submit to NS3

  5. INDUSTRY’S PERSPECTIVE- ad hoc Naphthalene Coalition - • Supportive of NS3 • Watching the symposium’s development closely • Will assess the symposium’s results carefully • Drafting outline for a research plan • Addresses: short term & long term research needs data insufficiencies regulatory uncertainty factors • Elements: exposure assessment, classic epidemiology, molecular epidemiology, genotoxicity, mechanism & mode of action, toxicology • Lessons learned from chloracetanilide pesticide MOA program • Under development/review for submission to NS3

  6. AFIOH-SPONSORED 1-DAY WORKSHOP“Naphthalene: exposure, epidemiology, human effects & cancer” AFIOH-SPONSORED 1-DAY WORKSHOP“Naphthalene: exposure, epidemiology, human effects & cancer” • Point of focus – seeming lack of epidemiological evidence for naphthalene-related cancer in humans • Different parties each had pieces of an incomplete puzzle • Assembled sampling of gov & industry experts • Morning: share & compare what we know highlight what we don’t know • Afternoon: generate issues/suggestions for research on uncertainties pertinent to improving naphthalene’s risk assessment • Action items identified • Meeting summary forthcoming • Support for submission to NS3

  7. QUESTIONS?

More Related